Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Up 758.6% in December

26 Dec 2025, 06:20 by Renee Jackson · The Cerbat Gem

Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 1,943,561 shares, a growth of 758.6% from the November 30th total of 226,362 shares. Approximately 18.8% of the shares of the company are sold short. Based on an average trading volume of 4,925,320 shares, the short-interest ratio is presently 0.4 days. Based on an average trading volume of 4,925,320 shares, the short-interest ratio is presently 0.4 days. Approximately 18.8% of the shares of the company are sold short.

Insider Transactions at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 24,579 shares of the firm’s stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $25.12, for a total value of $617,424.48. Following the sale, the director owned 779,652 shares in the company, valued at approximately $19,584,858.24. This trade represents a 3.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of Vor Biopharma stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $30.05, for a total transaction of $349,060.80. Following the completion of the sale, the insider directly owned 1,167,109 shares of the company’s stock, valued at approximately $35,071,625.45. This trade represents a 0.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 1,674,800 shares of company stock worth $49,516,960. Insiders own 0.45% of the company’s stock.

Institutional Trading of Vor Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of VOR. Woodline Partners LP purchased a new position in shares of Vor Biopharma during the 3rd quarter valued at $1,333,000. Polymer Capital Management HK LTD bought a new stake in Vor Biopharma during the third quarter valued at about $1,035,000. Millennium Management LLC raised its holdings in Vor Biopharma by 122.5% during the third quarter. Millennium Management LLC now owns 24,764 shares of the company’s stock valued at $1,207,000 after acquiring an additional 134,764 shares during the period. Fcpm Iii Services B.V. purchased a new position in shares of Vor Biopharma in the third quarter valued at about $18,496,000. Finally, Bank of America Corp DE boosted its stake in shares of Vor Biopharma by 679.3% in the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock worth $232,000 after acquiring an additional 4,144 shares during the period. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Trading Up 7.4%

VOR stock opened at $14.53 on Friday. The company’s 50-day moving average is $15.17. The stock has a market cap of $151.21 million, a PE ratio of -0.04 and a beta of 2.08. Vor Biopharma has a twelve month low of $2.62 and a twelve month high of $65.80.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on VOR shares. TD Cowen initiated coverage on Vor Biopharma in a research note on Wednesday, December 17th. They issued a “buy” rating on the stock. Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Stifel Nicolaus upgraded Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Wednesday, September 24th. Robert W. Baird upgraded shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $20.00 to $64.00 in a research note on Wednesday, October 15th. Finally, Wedbush initiated coverage on shares of Vor Biopharma in a report on Tuesday, November 25th. They issued a “neutral” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $68.43.

Get Our Latest Analysis on VOR

Vor Biopharma Company Profile

(Get Free Report)

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.